$
2.050
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.470
Open
1.470
VWAP
1.43
Vol
1.15M
Mkt Cap
5.12M
Low
1.410
Amount
1.65M
EV/EBITDA(TTM)
--
Total Shares
508.09K
EV
1.84M
EV/OCF(TTM)
--
P/S(TTM)
--
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Show More
2 Analyst Rating
up Image
387.80% Upside
Wall Street analysts forecast GRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRI is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
up Image
387.80% Upside
Current: 2.050
sliders
Low
10.00
Averages
10.00
High
10.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$10
2025-04-14
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Initiates
$10
2024-12-09
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$12 → $13
2024-12-05
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Initiates
$12
2024-10-08
Reason

Valuation Metrics

The current forward P/E ratio for GRI Bio Inc (GRI.O) is -0.51, compared to its 5-year average forward P/E of -0.16. For a more detailed relative valuation and DCF analysis to assess GRI Bio Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.16
Current PE
-0.51
Overvalued PE
0.09
Undervalued PE
-0.40

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.02
Current EV/EBITDA
-0.16
Overvalued EV/EBITDA
0.15
Undervalued EV/EBITDA
-0.11

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+61.00%
-3.05M
Operating Profit
FY2025Q1
YoY :
+61.42%
-3.05M
Net Income after Tax
FY2025Q1
YoY :
-94.26%
-5.80
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

GRI News & Events

Events Timeline

2025-07-01 (ET)
2025-07-01
08:47:39
GRI Bio completes enrollment in Phase 2a study of GRI-0621
select
2025-06-26 (ET)
2025-06-26
08:03:49
GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621
select
2025-05-22 (ET)
2025-05-22
08:10:13
GRI Bio presents preclinical data on GRI-0621
select
Sign Up For More Events

News

9.0
07-01Newsfilter
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF")
9.0
06-26NASDAQ.COM
GRI Bio, Inc. Reports Positive Interim Safety Results for GRI-0621 in Phase 2a Study for Idiopathic Pulmonary Fibrosis
4.0
05-27Benzinga
Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $34
Sign Up For More News

FAQ

arrow icon

What is GRI Bio Inc (GRI) stock price today?

The current price of GRI is 2.05 USD — it has increased 0 % in the last trading day.

arrow icon

What is GRI Bio Inc (GRI)'s business?

arrow icon

What is the price predicton of GRI Stock?

arrow icon

What is GRI Bio Inc (GRI)'s revenue for the last quarter?

arrow icon

What is GRI Bio Inc (GRI)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for GRI Bio Inc (GRI)'s fundamentals?

arrow icon

How many employees does GRI Bio Inc (GRI). have?

arrow icon

What is GRI Bio Inc (GRI) market cap?